{
    "2019-03-31": [
        [
            {
                "time": "",
                "original_text": "创新疫苗将进入第二波浪潮，重新梳理长期医药十年十倍四大主线【国盛医药张金洋团队】",
                "features": {
                    "keywords": [
                        "创新疫苗",
                        "第二波浪潮",
                        "长期医药",
                        "十年十倍",
                        "四大主线",
                        "国盛医药",
                        "张金洋团队"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "一季度基金回报喜人！最高斩获56%收益 冠军基金经理看好这两大板块",
                "features": {
                    "keywords": [
                        "一季度基金",
                        "回报喜人",
                        "56%收益",
                        "冠军基金经理",
                        "两大板块"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "未明确提及"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}